Galmed Pharmaceuticals’ shares are skyrocketing after the company announced ambitious plans to broaden its drug development activities, focusing on novel Aramchol-based drug combinations to combat resistant cancers and cardiac fibrosis. This expansion, coupled with Galmed’s low float and micro-cap status, has fueled significant volatility in the stock.